ID: ALA4473796

Max Phase: Preclinical

Molecular Formula: C14H10FN3

Molecular Weight: 239.25

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  Nc1ccc2ncc(-c3ccc(F)cc3)nc2c1

Standard InChI:  InChI=1S/C14H10FN3/c15-10-3-1-9(2-4-10)14-8-17-12-6-5-11(16)7-13(12)18-14/h1-8H,16H2

Standard InChI Key:  RYSRIWJYQZLLAR-UHFFFAOYSA-N

Associated Targets(non-human)

Astrocyte 64 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 239.25Molecular Weight (Monoisotopic): 239.0859AlogP: 3.02#Rotatable Bonds: 1
Polar Surface Area: 51.80Molecular Species: NEUTRALHBA: 3HBD: 1
#RO5 Violations: 0HBA (Lipinski): 3HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 3.32CX LogP: 2.65CX LogD: 2.65
Aromatic Rings: 3Heavy Atoms: 18QED Weighted: 0.66Np Likeness Score: -1.50

References

1. Le Douaron G, Ferrié L, Sepulveda-Diaz JE, Amar M, Harfouche A, Séon-Méniel B, Raisman-Vozari R, Michel PP, Figadère B..  (2016)  New 6-Aminoquinoxaline Derivatives with Neuroprotective Effect on Dopaminergic Neurons in Cellular and Animal Parkinson Disease Models.,  59  (13): [PMID:27341519] [10.1021/acs.jmedchem.6b00297]

Source